Emesis Clinical Trial
Official title:
A New Dual Function Oro-Dissolvable/Dispersible Meclizine HCL Tablet to Challenge Patient Inconvenience: In-Vitro Evaluation and In-Vivo Assessment in Human Volunteers
The main goal of this study is to develop a new oro-dissolvable/dispersible tablet that will augment the dual rapid absorption of MCZ from the buccal cavity as well as prolonging that from the GIT. A dual function tablet is expected to encompass an outer coat of the drug with special excipients that will rapidly disperse and the drug get dissolve and absorb in the buccal cavity and an inner core that will similarly, disperse to release MCZ coated nanoparticles in the saliva. The latter will be subsequently swallowed without water to be absorbed in a prolonged manner from the GIT. This will be advantageous for geriatric as well as pediatric patients, besides, those suffering from dysphagia. The pharmacokinetics profile of the prepared dual function tablet will be assessed in human volunteers through noncompartmental analysis.
Status | Recruiting |
Enrollment | 6 |
Est. completion date | December 1, 2020 |
Est. primary completion date | November 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 30 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Male aged between 30 and 40 years. - Body weight range of 75kg-95kg. - Healthy (defined as individuals who are free from significant nasal, cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, malignancy, endocrine, neurological and psychiatric disease as determined by history, physical examination and screening investigations). - Non-smoking status. This can include ex-smokers who have given up smoking for >1 year. - The subject is able and willing to give written informed consent to take part in the study and is available to complete all study measurements. Exclusion Criteria: - As a result of the medical interview, physical examination or screening investigations, the Investigator or appropriately qualified designee considers the subject unfit for the study. - The subject has a history of drug or any other allergy, which, in the opinion of the Investigator or appropriately qualified designee, contraindicates their participation, including known or suspected personal history or family history of adverse reactions or hypersensitivity to anti histamines. - The subject has participated in a study with a new molecular entity during the previous 3 months or any other study during the previous 2 months. - The subject drinks alcohol. - The subject is currently taking regular (or a course of) medication, prescribed (including all anti-allergy medication) or not (including over the counter medication or herbal remedies such as St Johns Wort). Paracetamol is an exception and will be permitted at daily doses of up to 4g following all doses of investigational product. - The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen. - The subject has tested positive for HIV. - The subject has a positive drugs of abuse and alcohol test. - Donation of blood (450 mL or more) within 2 months of screening. - Donation during the study would result in >500mL of blood being donated over a 56 day period - Significant cardiac conduction abnormalities. - Subjects with Perennial Allergic Rhinitis (PAR) and Seasonal Allergic Rhinitis (SAR), unless subjects with SAR are asymptomatic and it is outside of the pollen season - Subjects who are unable to comply with study procedures. |
Country | Name | City | State |
---|---|---|---|
Egypt | Mansoura University | Mansoura | Dakhalia |
Lead Sponsor | Collaborator |
---|---|
Mansoura University |
Egypt,
Aljimaee YH, El-Helw AR, Ahmed OA, El-Say KM. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. Drug Des Devel Ther. 2015 Mar 5;9:1379-92. doi: 10.2147/DDDT.S80294. eCollection 2015. — View Citation
Leach WT, Simpson DT, Val TN, Yu Z, Lim KT, Park EJ, Williams RO 3rd, Johnston KP. Encapsulation of protein nanoparticles into uniform-sized microspheres formed in a spinning oil film. AAPS PharmSciTech. 2005 Dec 6;6(4):E605-17. — View Citation
Wang K, Li L, Song Y, Ye X, Fu S, Jiang J, Li S. Improvement of pharmacokinetics behavior of apocynin by nitrone derivatization: comparative pharmacokinetics of nitrone-apocynin and its parent apocynin in rats. PLoS One. 2013 Jul 30;8(7):e70189. doi: 10.1 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | measuring the Meclizine HCl plasma concentration | Using high performance liquid chromatography to measure the change in plasma drug concentration? | over 24 hours after dosing | |
Primary | measuring the Meclizine HCl Area under the curve | measuring the Meclizine HCl Area under the curve using high performance liquid chromatography | over 24 hours after dosing | |
Primary | measuring the Meclizine HCl apparent clearance (CL/F) | measuring the Meclizine HCl apparent clearance (CL/F) using high performance liquid chromatography | over 24 hours after dosing | |
Primary | measuring the maximum blood concentration of Meclizine HCl | measuring the maximum blood concentration of Meclizine HCl using high performance liquid chromatography | over 24 hours after dosing | |
Primary | measuring the maximum blood concentration time of Meclizine HCl | measuring the maximum blood concentration time of Meclizine HCl using high performance liquid chromatography | over 24 hours after dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01913990 -
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
|
Phase 4 | |
Terminated |
NCT00869973 -
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
|
Phase 3 | |
Terminated |
NCT00869310 -
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
|
Phase 3 | |
Completed |
NCT04719286 -
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
|
N/A | |
Completed |
NCT01046240 -
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03478605 -
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
|
Phase 2 | |
Terminated |
NCT01148264 -
Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis
|
Phase 2 | |
Completed |
NCT01509417 -
Different Feeding Methods After Pyloromyotomy
|
N/A | |
Completed |
NCT00152867 -
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
|
Phase 3 | |
Completed |
NCT04182750 -
Promoting Safe Medication Use in Pregnancy in the Era of Real-World Data - The SafeStart Study
|
N/A | |
Completed |
NCT02980289 -
DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.
|
||
Completed |
NCT02602080 -
Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
|
||
Completed |
NCT04585841 -
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
|
Phase 1 | |
Completed |
NCT01414478 -
High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor
|
N/A | |
Not yet recruiting |
NCT02407600 -
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
|
Phase 2 |